New Delhi
Diabetes drug has a price war in the market. Indian pharmaceutical companies are launching cheap options for Type-2 diabetes drug ‘Empeglifflogen’. With this, patients will get this necessary medicine at a low price. Indian companies have taken advantage of this after the patent of this drug of Bohringer Ingelheim and Ellie Lily has taken advantage of it. Due to this, the price of this drug called ‘Jardans’ brand has dropped by 80%. Companies like Mankind Pharma, Glenmark and Alchem ​​are bringing different versions of this drug and FDC (fixed-dose combination) market. According to ICMR, India has more than 10.1 crore diabetes patients. People will be able to use it more than cheap medicine. This will bring a big change in the drug market. Foreign companies will have to reduce their prices.
According to Business Today’s report, the 10 Mg tablet of the first ‘Jardians’ was priced at Rs 58-60 and the price of 25 mg was Rs 65-70. Now Mankind Pharma is selling ‘Empeglide’ and ‘Empegrate’ 10 Mg Tablet for Rs 5.49 and 25 Mg Tablet for Rs 9.90. Glenmark’s ‘Glampa’ is getting Rs 8.50-10 per tablet. Alchem’s ‘Empanorm’ can be even more cheap. Experts believe that Indian companies want to strengthen their hold in diabetes market. According to IQVIA, generic drug sales in two years can be more than 60%.
Companies launched many brands
Glenmark has also launched FDCs such as ‘Glampa’ brand with 10 Mg and 25 Mg Tablet with ‘Glampa-L’ (ampegliflogen + linagliptin) and ‘Glampa-M’ (Empegliflogen + Metformin). Alok Malik, President and Head (India Formulations Business) of Glenmark Pharmaceuticals Limited, said, “Glenmark has a strong history in cardiometabolic care. The launch of the ‘Glampa’ range shows our commitment to provide high quality, low -cost drugs. Our advanced R&D ensures that this drug is as effective as the real branded medicine, but on a small part of its price. ‘
Mankind Pharma has launched several brands like ‘Ampaglide’, ‘Empegrate’ and ‘Dianaduo’. Rajiv Juneja, the company’s vice chairman and MD, said, ‘We believe that the price should never become a hindrance for the necessary medicines. That is why we have introduced ampegliflogen at a cheaper price so that millions of Indian diabetes patients can take it. The company is adopting a two -brand strategy to make its access to cities, small towns and villages. Also, in collaboration with endocrinologist and hospitals, is spreading awareness about the benefits of ampegliflose.
The size of the tablet is a small size
Alchem ​​laborators have kept the ‘Empanorm’ to 80% cheaper than the real branded medicine. To relieve fake medicines concern, the company has introduced an anti-counterfeit security band and material containing information for patients in many languages. According to Dr. Vikas Gupta, CEO of Elkem Laboratories, ‘The launch of ampegliflogen as an expansion of our chronic portfolio is especially in line with our mission to improve diabetes care in the management of heart and kidney disease.’ The company has also improved the size and coating of the tablet for elderly patients.
In addition to ‘Empanorm’ in the Empegliflogen range of Elkem, the ‘Empener L’ (Empegliflozine + Linagliptin), ‘Empenm Duo’ (Empegliflogen + Citagliptin) and ‘Empenorms M’ also include fdc. Dr. Gupta said, ‘One of the biggest obstacles in diabetes management is to take medicine regularly. By shortening the size of the tablet and by giving FDC, we want to take the medicine regularly and improve the health of the patients. ‘
Dr. Anoop Mishra, Chairman of Fortis C-Doc Hospital for Diabetes and Allied Sciences, said, “Ampogliflogen is given a lot, but due to low price, poor people will also be able to take it. This will increase regular intake of this best medicine.
How big is diabetic market?
Due to increasing cases of diabetes, the market of diabetes drugs is increasing rapidly worldwide. According to Fortune Business Insights, the price of this market in 2024 was around Rs 7,400,000 crore ($ 88.32 billion). It is estimated to reach Rs 19,600,000 crore (233.84 billion) by 2032. During this time the CAGR will be 12.7%. According to the Market Research Future, the market for diabetes care drugs in India was Rs 56,000 crore ($ 6.75 billion) in 2023. It is expected to reach Rs 95,000 crore ($ 11.46 billion) by 2032. During this time the CAGR will be 6.54%.